EditorialBroadening our Understanding of the Immune Landscape in Lynch Syndrome
References (14)
- et al.
Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial
Lancet
(2020) - et al.
The coding microsatellite mutation profile of PMS2-deficient colorectal cancer
Exp Mol Pathol
(2021) - et al.
Precision treatment and prevention of colorectal cancer-hope or hype?
Gastroenterology
(2020) - et al.
Recurrent frameshift neoantigen vaccine elicits protective immunity with reduced tumor burden and improved overall survival in a Lynch syndrome mouse model
Gastroenterology
(2021) - et al.
Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers
Gastroenterology
(2008) - et al.
Prevalence and penetrance of major genes and polygenes for colorectal cancer
Cancer Epidemiol Biomarkers Prev
(2017) - National Comprehensive Cancer Network. Genetic/familial high-risk assessment: colorectal (Version 1.2021). Plymouth...
There are more references available in the full text version of this article.
Cited by (2)
Is HLA type a possible cancer risk modifier in Lynch syndrome?
2023, International Journal of Cancer
Conflicts of interest The author discloses no conflicts.
© 2022 by the AGA Institute